ZNF503 and neoplasm: Analysis of single-cell datasets supported our conclusion that ZNF503-AS2 is expressed mainly in tumor cells and macrophages, and survival analyses showed that the effect of ZNF503-AS2 on OS was not dependent on macrophage infiltration; therefore, targeting ZNF503-AS2 may be effective in patients with high macrophage infiltration.